Literature DB >> 7826948

Inhibition of alloreactivity by mAb MR6: differential effects on IL-2- and IL-4- producing human T cells.

N Imami1, M Larché, M A Ritter.   

Abstract

mAb MR6 has previously been shown to block both IL-4-induced T cell proliferation and IL-4-dependent IgE production, suggesting a functional association between the antigen detected by MR6 (gp200-MR6) and the human IL-4 receptor. In this study the potential modulatory effects of mAb MR6 on IL-4 function have been further analysed in alloantigen-specific assays for cytotoxic and Th cell maturation, mature cytotoxic T cell killing, helper cell proliferation, and generation of IL-2- and IL-4-producing Th cells in a mixed lymphocyte reaction (MLR). Our data show that mAb MR6 has an inhibitory effect on both clonal expansion and maturation of cytotoxic T lymphocyte precursors within the alloreactive T cell population. mAb MR6 had no effect on the maturation of Th lymphocyte precursors (assayed by IL-2 production). However, this mAb had striking differential effects on cytokine production in MLR cultures, showing total ablation of IL-4 but no alteration of IL-2 levels in the supernatant medium. The absence of IL-4 from culture supernatants could be due to the fact that mAb MR6 is blocking cytokine production, that it is speeding up IL-4 internalization and utilization or that it inhibits the expansion of the T cell subset(s) that secretes IL-4. The data demonstrate that the action of mAb MR6 is focused on the IL-4-producing population and raise the possibility that gp200-MR6 may play an important role in this aspect of IL-4 function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826948     DOI: 10.1093/intimm/6.10.1575

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy.

Authors:  N Imami; G A Hardy; M R Nelson; S Morris-Jones; R Al-Shahi; C Antonopoulos; B Gazzard; F M Gotch
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

2.  Intrathymic function of the human cortical epithelial cell surface antigen gp200-MR6: single-chain antibodies to evolutionarily conserved determinants disrupt mouse thymus development.

Authors:  D B Palmer; T Crompton; M B Marandi; A J George; M A Ritter
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

3.  A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection.

Authors:  Nesrina Imami; Antonio Pires; Gareth Hardy; Jamie Wilson; Brian Gazzard; Frances Gotch
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

4.  Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy.

Authors:  A Pires; M Nelson; A L Pozniak; M Fisher; B Gazzard; F Gotch; N Imami
Journal:  J Immune Based Ther Vaccines       Date:  2005-09-25

5.  Loss of interleukin 4 receptor-associated molecule gp200-MR6 in human breast cancer: prognostic significance.

Authors:  L Kaklamanis; M I Koukourakis; R Leek; A Giatromanolaki; M Ritter; R Whitehouse; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

6.  Differential expression of gp200-MR6 molecule in benign hyperplasia and down-regulation in invasive carcinoma of the breast.

Authors:  A A al-Tubuly; Y A Luqmani; S Shousha; D Melcher; M A Ritter
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

7.  Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin 4 receptor (CD 124).

Authors:  M F Tungekar; K C Gatter; M A Ritter
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.